Suppr超能文献

1990年至2030年中国肝癌负担的长期趋势及未来预测。

Long-term trends and future projections of liver cancer burden in China from 1990 to 2030.

作者信息

Zhan Zhouwei, Chen Bijuan, Huang Rui, Lin Wei, Lan Shuangting, Yao Xintong, Huang Shuqi, Lin Wenlong, Xu Shaohua, Zhou Sijing, Yu Jiami, Wang Xiaojie, Lin Xiaoyan, Guo Zengqing

机构信息

Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, No. 420 Fuma Road, Fuzhou, 350014, Fujian, China.

Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, 350014, Fujian, China.

出版信息

Sci Rep. 2025 Apr 16;15(1):13120. doi: 10.1038/s41598-025-96615-1.

Abstract

Liver cancer remains a significant public health issue in China, exhibiting high incidence, mortality, and burden. Understanding its temporal trends and projections is essential for designing targeted prevention and treatment strategies. This study analyzes long-term trends in liver cancer incidence, prevalence, mortality, and burden from 1990 to 2021, assessing age, period, and cohort effects, and projecting future trends. Data on liver cancer incidence, prevalence, mortality, disability-adjusted life years (DALYs), years lived with disability (YLDs), and years of life lost (YLLs) were analyzed from 1990 to 2021. Joinpoint regression analysis, age-period-cohort (APC) analysis, and BAPC modeling were applied to examine trends and project future trends. Decomposition analysis examined contributions of aging, epidemiological changes, and population growth. The study also compared China's liver cancer trends with global data. From 1990 to 2021, China experienced a decrease in age-standardized rates for liver cancer incidence, prevalence, mortality, and burden. Notably, Age-standardized incidence rates (ASIR) exhibited a decline after 2016, with a significant reduction in the male population. In 2021, there were 196,637 new cases of liver cancer in China, with a higher burden in males. ASIR were 14.34 per 100,000 for males and 4.89 per 100,000 for females. Mortality also followed a declining trend, with a notable decrease in age-standardized mortality rates. The age-standardized mortality rate (ASMR) for males was 12.4 per 100,000, significantly higher than for females (4.57 per 100,000) in 2021. Additionally, the age-standardized prevalence rate (ASPR) was 20.0 for males and 6.64 for females, with 265,539 total cases. The burden, measured by DALYs, YLDs, and YLLs, also showed a notable decline in age-standardized rates and significant gender disparities. Despite this, the absolute number of cases, deaths, and DALYs has continued to rise due to population growth and aging, with males bearing a significantly higher burden than females. The study also highlights the impact of aging, population growth, and epidemiological changes on liver cancer incidence and mortality in China. Projections for 2030 suggest a continued decrease in liver cancer incidence, especially among females, reflecting the effectiveness of public health interventions and medical advancements. However, gender disparities remain significant, and further efforts are needed to reduce the overall liver cancer burden, with an emphasis on early detection and prevention strategies.

摘要

肝癌在中国仍然是一个重大的公共卫生问题,其发病率、死亡率和负担都很高。了解其时间趋势和预测对于制定有针对性的预防和治疗策略至关重要。本研究分析了1990年至2021年肝癌发病率、患病率、死亡率和负担的长期趋势,评估了年龄、时期和队列效应,并预测了未来趋势。分析了1990年至2021年肝癌发病率、患病率、死亡率、伤残调整生命年(DALYs)、带病生存年数(YLDs)和寿命损失年数(YLLs)的数据。采用Joinpoint回归分析、年龄-时期-队列(APC)分析和BAPC建模来研究趋势并预测未来趋势。分解分析考察了老龄化、流行病学变化和人口增长的贡献。该研究还将中国的肝癌趋势与全球数据进行了比较。1990年至2021年期间,中国肝癌发病率、患病率、死亡率和负担的年龄标准化率均有所下降。值得注意的是,年龄标准化发病率(ASIR)在2016年后呈下降趋势,男性人口显著减少。2021年,中国有196,637例新发肝癌病例,男性负担更高。男性的ASIR为每10万人14.34例,女性为每10万人4.89例。死亡率也呈下降趋势,年龄标准化死亡率显著下降。2021年男性的年龄标准化死亡率(ASMR)为每10万人12.4例,显著高于女性(每10万人4.57例)。此外,年龄标准化患病率(ASPR)男性为20.0,女性为6.64,总病例数为265,539例。以DALYs、YLDs和YLLs衡量的负担在年龄标准化率方面也显著下降,且存在显著的性别差异。尽管如此,由于人口增长和老龄化,病例、死亡和DALYs的绝对数量持续上升,男性负担显著高于女性。该研究还强调了老龄化、人口增长和流行病学变化对中国肝癌发病率和死亡率的影响。对2030年的预测表明,肝癌发病率将持续下降,尤其是女性,这反映了公共卫生干预措施和医学进步的有效性。然而,性别差异仍然显著,需要进一步努力降低总体肝癌负担,重点是早期检测和预防策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15a0/12003824/5f4bbaf244e9/41598_2025_96615_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验